Produktinformation
- Dihydroergotamine
- DHE
- MAP 0004
- 9,10-Dihydroergotamine
- (5'alpha,10alpha)-9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotaman-3',6',18-trione
- (5'Alpha,10Alpha)-5'-Benzyl-12'-Hydroxy-2'-Methyl-3',6',18-Trioxo-9,10-Dihydroergotaman
- (5′α,10α)-9,10-Dihydro-12′-hydroxy-2′-methyl-5′-(phenylmethyl)ergotaman-3′,6′,18-trione
- 8H-Oxazolo[3,2-a]pyrrolo[2,1-c]pyrazine, ergotaman-3′,6′,18-trione deriv.
- Dihidroergotamina
- Dihydroergotamin
- Mehr Synonyme anzeigen
- Dihydroergotamine base
- Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'α,10α)-
- Ergotaman-3′,6′,18-trione, 9,10-dihydro-12′-hydroxy-2′-methyl-5′-(phenylmethyl)-, (5′α,10α)-
- Ergotamine, 9,10-dihydro-
- Indolo[4,3-fg]quinoline, ergotaman-3′,6′,18-trione deriv.
- Map 0004
Applications Levadex is an intermediate in the synthesis of 2’-Epidihydroergotamine (E584910), which is an ergot alkaloid that exhibits potential neuroprotective properties against degenerative diseases.
References French, W.N., et al.: J. Pharma. Sci., 54, 1515 (1965);